Skip to content
Screener

10x Genomics, Inc. TXG Q2 2026 earnings

Reported August 6, 2026 · After market close

Revenue$151.0MBeat by $4.4M
EPS-$0.14Beat by $0.10
Revenue estimate$146.7M
EPS estimate-$0.24
“The story of the quarter was the extraordinary customer response to Atera. We are highly encouraged by the engagement across the research ecosystem and the very strong early order flow. Combined with the continued momentum across the rest of the business and our strong operating foundation, we are uniquely well-positioned for the opportunities ahead.”
Serge Saxonov

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$147.3M
EPS estimate-$0.27

Financials

Q2 2026

Income statement

See full
Revenue$151.0M-12.6%
Gross profit$112.5M-10.1%
Operating income-$19.6M-165%
Net income-$17.9M-152%
EPS (diluted)-$0.14-150%

Balance sheet

See full
Cash & equivalents$502.5M+26.4%
Total debt$78.8M-9.2%
Total equity$825.5M+6.8%
Total assets$1.0B+5.1%

Cash flow

See full
Operating cash flow$17.0M-4.1%
CapEx$1.6M+0.6%
Free cash flow$15.4M-4.6%

Valuation & ratios

Valuation

as of 09/18/26
See full
Market cap$10.03B+507%
Enterprise value$9.6B+616%
P/S16.3×+13.7×

Profitability

See full
Gross margin70%+0.5pp
Operating margin-14.3%-1.1pp
Net margin-12.2%-0.8pp
FCF margin19.7%+10.9pp

Returns & leverage

See full
Return on equity-9.4%-1.4pp
Debt / equity0.1×0.0×
Current ratio5.7×-0.1×

Segments

By product

See full
Products and services revenue$149.1M+2.7%
Services$10.7M+26.0%
Spatial$4.6M-47.8%
Single Cell$3.1M-46.1%
License and royalty revenue$1.9M-93.0%

By geography

See full
Europe, Middle East and Africa$40.0M+15.1%
Asia-Pacific (excluding China)$11.1M+25.1%
Americas (excluding United States)$2.9M+9.4%

FAQ

When did 10x Genomics, Inc. report Q2 2026 earnings?
10x Genomics, Inc. (TXG) reported Q2 2026 earnings on August 6, 2026 after market close.
What were 10x Genomics, Inc.'s Q2 2026 revenue and EPS?
10x Genomics, Inc. reported revenue of $151.0M and eps of $-0.14 for Q2 2026.
Did 10x Genomics, Inc. beat estimates in Q2 2026?
Revenue beat the consensus estimate of $146.7M by $4.4M. EPS beat the consensus estimate of $-0.24 by $0.10.
How did 10x Genomics, Inc.'s Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 12.6% from $172.9M a year earlier.
Where can I find 10x Genomics, Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001628280-26-054273) and the 10-Q periodic report (0001628280-26-054491) directly on SEC EDGAR. The filing index links above go to sec.gov.